These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21984295)

  • 41. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
    Tankó LB
    Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Denosumab - a new option in the treatment of osteoporosis].
    Franek E
    Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Denosumab: anti-RANKL antibody.
    Miller PD
    Curr Osteoporos Rep; 2009 Mar; 7(1):18-22. PubMed ID: 19239825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The RANKL pathway and denosumab.
    Dore RK
    Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of osteoporosis with Denosumab].
    Ferrari S
    Ther Umsch; 2012 Mar; 69(3):182-6. PubMed ID: 22403111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE; Riche DM
    Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
    J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Denosumab for the treatment of osteoporosis and cancer-related conditions.
    Lewiecki EM; Bilezikian JP
    Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Denosumab.
    Pageau SC
    MAbs; 2009; 1(3):210-5. PubMed ID: 20065634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
    Deodhar A; Dore RK; Mandel D; Schechtman J; Shergy W; Trapp R; Ory PA; Peterfy CG; Fuerst T; Wang H; Zhou L; Tsuji W; Newmark R
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):569-74. PubMed ID: 20391513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
    Tokuyama N; Tanaka S
    Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Denosumab (Prolia): A new option in the treatment of osteoporosis.
    Belavic JM
    Nurse Pract; 2011 Jan; 36(1):11-2. PubMed ID: 21173630
    [No Abstract]   [Full Text] [Related]  

  • 60. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
    J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.